Afstyla 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0042 
Update of section 5.1 of the SmPC  in order to update 
10/06/2022 
SmPC, 
Submission of study results of Study 3001 which aimed at 
efficacy and safety information based on final results 
Labelling and 
investigating the safety and efficacy of Afstyla in previously 
from study 3001 listed as a category 3 study in the 
RMP;  this is an open label, multicenter extension 
study to assess the Safety and Efficacy of Afstyla in 
subjects with severe Hemophilia A. In addition, the 
PL 
treated (PTPs) and previously untreated patients (PUPs) 
with severe haemophilia A. 
For more information, please refer to the Summary of 
Product Characteristics. 
1 Notifications are issued for type I  variations and Article 61(3) notifications (unless part of a group including a type II  variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II,  labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC  (Summary  of Product Characteristics), Annex II,  Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union 
 
 
 
 
 
 
  
 
 
 
MAH took the opportunity to update the list of local 
representatives in the Package Leaflet. The RMP 
version 6.0 has also been submitted. 
C.I.4  - Change(s) in the SPC,  Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0044/G 
This was an application for a group of variations. 
03/06/2022 
n/a 
B.II.b.5.z  - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.3.a  - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.I.a.4.b  - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.2.a  - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a  - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC  Recommendation - maintenance 
/202107 
lonoctocog alfa 
IB/0041/G 
This was an application for a group of variations. 
04/02/2022 
n/a 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.z  - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.a  - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0039 
B.I.b.2.e  - Change in test procedure for AS or 
09/09/2021 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
02/09/2021 
n/a 
PRAC  Recommendation - maintenance 
/202101 
lonoctocog alfa 
R/0037 
Renewal of the marketing authorisation. 
24/06/2021 
20/08/2021 
SmPC,  Annex 
Based on the review of data on quality, safety and efficacy, 
II,  Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Afstyla in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
11/02/2021 
n/a 
PRAC  Recommendation - maintenance 
/202007 
lonoctocog alfa 
IA/0036 
B.II.e.7.a  - Change in supplier of packaging 
01/12/2020 
n/a 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC  Recommendation - maintenance 
/202001 
lonoctocog alfa 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0033 
B.II.e.1.b.2  - Change in immediate packaging of the 
18/06/2020 
n/a 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
IA/0034 
B.II.d.2.a  - Change in test procedure for the finished 
29/05/2020 
n/a 
product - Minor changes to an approved test 
procedure 
II/0029/G 
This was an application for a group of variations. 
14/05/2020 
n/a 
B.I.b.1.e  - Change in the specification parameters 
and/or limits of an AS,  starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the AS and/or the FP 
B.I.b.1.g  - Change in the specification parameters 
and/or limits of an AS,  starting 
material/intermediate/reagent - Widening of the 
approved specs for starting mat./intermediates, 
which may have a significant effect on the quality of 
the AS and/or the FP 
B.I.b.1.b  - Change in the specification parameters 
and/or limits of an AS,  starting 
material/intermediate/reagent - Tightening of 
specification limits 
IB/0031 
B.I.a.2.a  - Changes in the manufacturing process of 
13/03/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0030 
C.I.11.b  - Introduction of, or change(s) to, the 
12/03/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC  Recommendation - maintenance 
/201907 
lonoctocog alfa 
IB/0027 
B.I.a.2.a  - Changes in the manufacturing process of 
25/11/2019 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IG/1160/G 
This was an application for a group of variations. 
24/10/2019 
03/04/2020 
SmPC, 
B.II.e.5.b  - Change in pack size of the finished 
product - Deletion of a pack size(s) 
B.II.e.5.b  - Change in pack size of the finished 
product - Deletion of a pack size(s) 
Labelling and 
PL 
IB/0025/G 
This was an application for a group of variations. 
19/09/2019 
n/a 
B.I.z  - Quality change - Active substance - Other 
variation 
B.II.z  - Quality change - Finished product - Other 
variation 
II/0023/G 
This was an application for a group of variations. 
12/09/2019 
n/a 
B.I.a.4.z  - Change to in-process tests or limits 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.f  - Change in the specification parameters 
and/or limits of an AS,  starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
B.I.b.2.e  - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.1.e  - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.2.d  - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC  Recommendation - maintenance 
/201901 
lonoctocog alfa 
IB/0021/G 
This was an application for a group of variations. 
29/06/2019 
03/04/2020 
SmPC, 
B.II.e.6.a  - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1  - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IA/0022/G 
This was an application for a group of variations. 
29/05/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS,  starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.e.7.a  - Change in supplier of packaging 
Page 7/10 
 
 
 
 
 
 
 
 
 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.III.2.z  - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
IB/0018 
B.II.d.2.a  - Change in test procedure for the finished 
22/05/2019 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0017 
C.I.z  - Changes (Safety/Efficacy) of Human and 
12/05/2019 
03/04/2020 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0020 
B.IV.1.a.1  - Change of a measuring or administration 
04/04/2019 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0016 
C.I.11.z  - Introduction of, or change(s) to, the 
30/01/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
17/01/2019 
n/a 
PRAC  Recommendation - maintenance 
/201807 
lonoctocog alfa 
IB/0014 
B.I.a.2.z  - Changes in the manufacturing process of 
10/01/2019 
n/a 
the AS - Other variation 
IA/0015 
B.I.a.4.a  - Change to in-process tests or limits 
18/12/2018 
n/a 
applied during the manufacture of the AS - 
Tightening of in-process limits 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0013 
Minor change in labelling or package leaflet not 
28/11/2018 
25/02/2019 
PL 
connected with the SPC  (Art. 61.3 Notification) 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC  Recommendation - maintenance 
/201801 
lonoctocog alfa 
IA/0011 
B.II.d.1.d  - Change in the specification parameters 
31/05/2018 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
IB/0008 
B.I.e.5.c  - Implementation of changes foreseen in an 
01/03/2018 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
II/0007 
C.I.4  - Change(s) in the SPC,  Labelling or PL due to 
22/02/2018 
25/02/2019 
SmPC, 
new quality, preclinical, clinical or pharmacovigilance 
data 
Labelling and 
PL 
PSUSA/10559
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC  Recommendation - maintenance 
/201707 
lonoctocog alfa 
IB/0009 
B.II.b.3.a  - Change in the manufacturing process of 
05/01/2018 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
II/0001 
B.I.e.2  - Introduction of a post approval change 
12/10/2017 
n/a 
management protocol related to the AS 
IB/0006 
B.I.a.2.z  - Changes in the manufacturing process of 
11/10/2017 
n/a 
the AS - Other variation 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
B.I.a.4.z  - Change to in-process tests or limits 
13/07/2017 
n/a 
applied during the manufacture of the AS - Other 
variation 
IA/0004/G 
This was an application for a group of variations. 
29/05/2017 
n/a 
B.II.b.3.a  - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a  - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
N/0002 
Minor change in labelling or package leaflet not 
21/04/2017 
25/02/2019 
PL 
connected with the SPC  (Art. 61.3 Notification) 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
